281 related articles for article (PubMed ID: 30462521)
1. Evaluating the safety of emicizumab in patients with hemophilia A.
Langer AL; Etra A; Aledort L
Expert Opin Drug Saf; 2018 Dec; 17(12):1233-1237. PubMed ID: 30462521
[TBL] [Abstract][Full Text] [Related]
2. Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: Review of the real-world evidence.
Kenet G; Fujii T
Haemophilia; 2024 Mar; 30(2):267-275. PubMed ID: 38291654
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology of emicizumab for the treatment of hemophilia A.
Yoneyama K; Schmitt C; Portron A; Kiialainen A; Kotani N; Jaminion F; Retout S; Adamkewicz JI
Expert Rev Clin Pharmacol; 2023; 16(9):775-790. PubMed ID: 37529848
[TBL] [Abstract][Full Text] [Related]
4. Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A.
Zhou ZY; Raimundo K; Patel AM; Han S; Ji Y; Fang H; Zhong J; Betts KA; Mahajerin A
J Manag Care Spec Pharm; 2020 Sep; 26(9):1109-1120. PubMed ID: 32452276
[TBL] [Abstract][Full Text] [Related]
5. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
[TBL] [Abstract][Full Text] [Related]
6. Safety first: Tracking adverse events associated with new therapies for people with hemophilia.
Recht M
J Thromb Haemost; 2021 Jan; 19 Suppl 1():3-5. PubMed ID: 33331044
[No Abstract] [Full Text] [Related]
7. Efficacy/effectiveness and safety of emicizumab prophylaxis of people with hemophilia A: a systematic review and meta-analysis.
Muniz RL; Camelo RM; Araújo MS; Barbosa MM; Guerra AA; Acurcio FA; Alvares-Teodoro J
Expert Rev Hematol; 2023; 16(12):1087-1097. PubMed ID: 38066708
[TBL] [Abstract][Full Text] [Related]
8. Non-additive effect on thrombin generation when a plasma-derived factor VIII/von Willebrand factor (FVIII/VWF) is combined with emicizumab in vitro.
Bravo MI; Raventós A; Pérez A; Costa M; Willis T
J Thromb Haemost; 2020 Aug; 18(8):1934-1939. PubMed ID: 32379931
[TBL] [Abstract][Full Text] [Related]
9. Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data.
Cho H; Yoo KY; Shin JY; Lee EK; Choi B
J Thromb Haemost; 2024 Jun; 22(6):1640-1648. PubMed ID: 38395359
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
Callaghan MU; Negrier C; Paz-Priel I; Chang T; Chebon S; Lehle M; Mahlangu J; Young G; Kruse-Jarres R; Mancuso ME; Niggli M; Howard M; Bienz NS; Shima M; Jiménez-Yuste V; Schmitt C; Asikanius E; Levy GG; Pipe SW; Oldenburg J
Blood; 2021 Apr; 137(16):2231-2242. PubMed ID: 33512413
[TBL] [Abstract][Full Text] [Related]
11. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
[TBL] [Abstract][Full Text] [Related]
12. Emicizumab promotes factor Xa generation on endothelial cells.
Fager AM; Ellsworth P; Key NS; Monroe DM; Hoffman M
J Thromb Haemost; 2024 Jun; 22(6):1605-1615. PubMed ID: 38460838
[TBL] [Abstract][Full Text] [Related]
13. The effect of emicizumab and bypassing agents in patients with hemophilia - An in vitro study.
Schultz NH; Glosli H; Bjørnsen S; Holme PA
Res Pract Thromb Haemost; 2021 Jul; 5(5):e12561. PubMed ID: 34263107
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of prophylaxis with emicizumab in hemophilia A: A study of 13 patients.
Ocaña Gómez MÁ; Ferrer Machín A; Vera Cabrera M; Álvarez Tosco KI; Ríos de Paz M; de Dios García MD
Med Clin (Barc); 2024 Feb; 162(3):134-137. PubMed ID: 37599198
[TBL] [Abstract][Full Text] [Related]
15. An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A.
Takeyama M; Nogami K; Matsumoto T; Noguchi-Sasaki M; Kitazawa T; Shima M
J Thromb Haemost; 2020 Apr; 18(4):825-833. PubMed ID: 31984625
[TBL] [Abstract][Full Text] [Related]
16. Emicizumab: the hemophilia A game-changer.
Alcedo Andrade PE; Mannucci PM; Kessler CM
Haematologica; 2024 May; 109(5):1334-1347. PubMed ID: 37916312
[TBL] [Abstract][Full Text] [Related]
17. Should emicizumab be used in patients with acquired hemophilia A?
Tiede A; Kemkes-Matthes B; Knöbl P
J Thromb Haemost; 2021 Mar; 19(3):637-644. PubMed ID: 33306259
[TBL] [Abstract][Full Text] [Related]
18. Low-dose emicizumab prophylaxis in patients with severe hemophilia A: a retrospective study bringing new hope for our patients.
Patil R; Shanmukhaiah C; Gogtay NJ; Pandey P; Patil K; Jijina F; Madkaikar M
J Thromb Haemost; 2024 Apr; 22(4):1024-1030. PubMed ID: 38160726
[TBL] [Abstract][Full Text] [Related]
19. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents.
Hartmann R; Feenstra T; Valentino L; Dockal M; Scheiflinger F
J Thromb Haemost; 2018 Jun; ():. PubMed ID: 29888855
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan.
Shen MC; Chou SC; Chiou SS; Lin PC; Chen YC; Lin HY; Lee YC; Huang CE; Weng TF; Huang TH; Chung CY; Chen JS; Chen SH; Cheng SN; Hsiao CC; Huang YM; Chen SH; Yu YB; Lin SC; Lin CY; Peng CT; Wang JD;
Haemophilia; 2023 Nov; 29(6):1499-1508. PubMed ID: 37819166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
